Range of eligible individuals: CDEC reviewed the uncertainty in the volume of individuals with reasonably extreme to intense hemophilia B in Canada qualified for etranacogene dezaparvovec. Scientific specialists consulted by CADTH indicated that some individuals that are categorized as obtaining gentle or moderate sickness may have a critical bleeding phenotype, https://hemgenix39371.pages10.com/everything-about-hemgenix-71121571